Ribosomal protein L13a pseudogene 17 (RPL13AP17)

**Ribosomal protein L13a pseudogene 17 (RPL13AP17)** is a processed pseudogene of the gene encoding ribosomal protein L13a. Pseudogenes are gene copies that have lost the ability to encode a functional protein due to mutations or lack of regulatory elements[2][4][7]. RPL13AP17 is annotated in the human genome, but there is no evidence it produces a functional protein or serves as a therapeutic target (such as receptor, enzyme, transporter, etc.). Like many ribosomal protein pseudogenes, it is considered non-functional, though some pseudogenes may have regulatory roles at the RNA level in rare cases[8]. There is no evidence of this pseudogene being involved in any specific biological process, disease, or targeted by drugs, and it is not relevant as a clinical or therapeutic target.\n\n**Clarification:**\n- RPL13AP17 is a *pseudogene* and not a functional gene, receptor, enzyme, or drug target—unlike the actual ribosomal protein L13a (encoded by RPL13A), which does have known biological roles[1][3][5].\n- "Is_incorrect" is marked true because this gene is not an established target for drugs or therapeutics and the pseudogene is often listed in databases only as a non-coding genomic element with no functional or pharmacological relevance[2][4][6][7].\n- There is no evidence in the available literature or major databases (GeneCards, Monarch Initiative, NCBI) that RPL13AP17 encodes any meaningful product, regulates disease, or serves as a biomarker. Its functional impact, if any, would be highly speculative and not accepted in current biology[2][4][7][8].

Other names

RPL13AP17